---
title: "Weekly Recap | Propanc Biopharma -25.19%, trading near range lows"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298101846.md"
description: "Propanc Biopharma (PPCB.US) fell 25.19% this week to close at $1.01, while the S&P 500 gained 0.09%, leaving the stock roughly 25.28 percentage points behind the benchmark. The week opened strongly but faded fast: the shares rose to an intraday high of $1.48 on Monday (31 Aug), then sold off day by day. By Friday (4 Sep), the stock briefly touched $0.9715, close to the 52-week low of $0.95 set in late July, before recovering above $1.00."
datetime: "2026-09-05T07:57:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298101846.md)
  - [en](https://longbridge.com/en/news/298101846.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298101846.md)
generator: "portal-rs"
---

# Weekly Recap | Propanc Biopharma -25.19%, trading near range lows

## The Week

Propanc Biopharma (PPCB.US) fell 25.19% this week to close at $1.01, while the S&P 500 gained 0.09%, leaving the stock roughly 25.28 percentage points behind the benchmark. The week opened strongly but faded fast: the shares rose to an intraday high of $1.48 on Monday (31 Aug), then sold off day by day. By Friday (4 Sep), the stock briefly touched $0.9715, close to the 52-week low of $0.95 set in late July, before recovering above $1.00. There were no company-specific catalysts; the only news mention was a pre-market movers note on Monday. The move fits the pattern of momentum-driven volatility in a low-float stock.

## The Week Ahead

Macro data dominate the calendar. NFIB small business optimism is due Tuesday (8 Sep), followed on Thursday (10 Sep) by initial jobless claims, final demand PPI, existing home sales and wholesale sales, plus a 10-year Treasury auction. PPCB.US has no scheduled company events. The key watchpoint is whether the price can hold above $1.00 and whether the elevated daily volume — averaging around 500,000 shares this week — carries into next week. For a volatile micro-cap name, macro releases tend to act mainly as sentiment triggers rather than fundamental drivers.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [PPCB.US](https://longbridge.com/en/quote/PPCB.US.md)

## Related News & Research

- [Propanc Biopharma plans Phase 1b first-in-human PRP trial in advanced solid tumors starting February 2027](https://longbridge.com/en/news/299184214.md)
- [Propanc Biopharma plans first-in-human Phase 1b PRP trial start in February 2027](https://longbridge.com/en/news/298458683.md)
- [China central bank adviser says AI could deepen supply-demand imbalance](https://longbridge.com/en/news/299523697.md)
- [Anthropic weighs launching a new AI model ahead of IPO: Reuters](https://longbridge.com/en/news/299525877.md)
- [RTB Digital to buy 49% stake in Paradium.AI for USD 89.56 million](https://longbridge.com/en/news/299489040.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**